Firma Kuros Biosciences, Autor bei News-Research

Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

1. Februar 2024 Firma Kuros BiosciencesPosted in Forschung und EntwicklungTagged biomed, bone, cells, clinical, ecm, graft, kuros, magnetos, new, patients, posterolateral, risks, spinal, spine, statements

Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it will present at the CG 2024 Musculoskeletal Conference, to be held in San […]

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

31. Januar 2024 Firma Kuros BiosciencesPosted in AllgemeinTagged bone, ecm, flex, gold, graft, implant, kuros, magnetos, market, maxa, patients, posterolateral, putty, statements, with

MagnetOs™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for interbody use Kuros continues expansion of the MagnetOs franchise with launch of MagnetOs […]

Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA

4. Januar 2024 Firma Kuros BiosciencesPosted in Forschung und EntwicklungTagged autograft, bone, ecm, gold, graft, implant, kuros, magnetos, market, maxa, patients, posterolateral, putty, statements, with

. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the challenging posterior spinal fusion approach, demonstrates a fusion rate of […]

Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA

27. Dezember 2023 Firma Kuros BiosciencesPosted in MedizintechnikTagged bone, ddd, ecm, fibrin, gold, graft, kuros, magnetos, market, maxa, patients, posterolateral, pth, statements, with

In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat real life patient population (20% smokers). In the STRUCTURE […]

Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages

28. November 202329. November 2023 Firma Kuros BiosciencesPosted in FirmeninternTagged biomed, bone, ecm, extender, fibrin, flex, graft, kuros, magnetos, market, patients, posterolateral, pth, statements, with

MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interbody use MagnetOs can now be used on-label in any interbody cage […]

Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management

12. Oktober 202316. Oktober 2023 Firma Kuros BiosciencesPosted in Finanzen / BilanzenTagged bone, chf, ebitda, ecm, fibrin, griffin, kuros, magnetos, market, patients, posterolateral, pth, revenue, statements, with

Direct MagnetOs sales grew to CHF 20.4 million in the first nine months of 2023, climbing from CHF 8.1 million in the same period in 2022. Total medical device […]

Kuros Biosciences Reports Results for First Half 2023

9. August 2023 Firma Kuros BiosciencesPosted in Finanzen / BilanzenTagged bone, chf, ebitda, ecm, fibrin, graft, kuros, magnetos, market, patients, posterolateral, pth, revenue, statements, with

. Financial Highlights Direct MagnetOs sales increased by 148% from CHF 4.9 million to CHF 12.2 million, total revenue from medical devices rose from CHF 5.7 million to CHF 12.9 […]

Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial

13. Juli 202313. Juli 2023 Firma Kuros BiosciencesPosted in Forschung und EntwicklungTagged bone, clinical, ddd, fibrin, fuse, graft, kuros, market, patients, posterolateral, pth, spinal, statements, tlif, with

First investigational trial of drug-biologic bone graft for spinal fusion 50 patients have been enrolled in the Phase 2 trial Potential to address $2.2B market opportunity Schlieren (Zurich), Switzerland, July […]

Annual General Meeting of Kuros Biosciences approves all resolutions

8. Mai 20238. Mai 2023 Firma Kuros BiosciencesPosted in FirmeninternTagged ??forward, bonds, bone, financial, graft, its, kuros, looking, report, results, risks, shareholders, shares, statements, van

Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today. The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and […]

Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023

27. April 202329. April 2023 Firma Kuros BiosciencesPosted in Finanzen / BilanzenTagged bone, chf, ebitda, ecm, fibrin, graft, implants, kuros, magnetos, market, patients, posterolateral, pth, statements, with

Direct MagnetOs sales climbed from CHF 2.0 million in Q1 2022 to CHF 5.4 million in Q1 2023. Total medical device sales accelerate from 2.6 million to CHF 5.6 million […]